DGAP-News

Glycotope GmbH and Octapharma AG: Glycotope and Octapharma enter exclusive worldwide license agreement on human blood coagulation factors - Seite 2

by this agreement complement Octapharma's blood coagulation and protein
portfolio and push additional focus into recombinant fully human optimized
as well as long-lasting factors."

Under the terms of the agreement, Octapharma will gain exclusive worldwide
rights to research, develop and commercialize candidates from Glycotope's
preclinical human blood coagulation factor portfolio based on Glycotope's
proprietary GlycoExpress(TM) platform. Glycotope will receive an upfront
payment and is eligible for substantial research and manufacturing related
revenues during the life of the agreement for a series of products. In
addition, Glycotope will receive further development and sales related
milestone payments and royalties for a defined number of projects.
Octapharma will be responsible for all research and development costs and
will pursue major activities within the clinical development by its own
development organization.

Glycotope has developed a novel long-lasting technology basket for
generating proteins with largely improved pharmacokinetic properties. So
far significant improvements in key pharmacokinetic properties could be
achieved for complex blood coagulation factors. This technology is suitable
for half-life extension of blood coagulation factors as well as other
proteins for improved patient compliance and represents the newest member
in the Glycotope platform technologies.

"Octapharma's ongoing commitment to hemophilia research, combined with its
experience in developing and marketing hemophilia and other blood protein
factor products, makes them an excellent partner for our human blood
coagulation portfolio, GlycoExpress(TM) technology and long-lasting
technologies," added Dr. Steffen Goletz, CEO/CSO at Glycotope. "We very
much look forward to working with the scientists and clinical development
teams at Octapharma to exploit the therapeutic potential of our portfolio
and technologies for the benefit of patients needing improved, reliable and
potentially more convenient treatment options of their hemophilia
conditions."

"We are very pleased to welcome Octapharma, a global player in hematology
products, as our strategic partner. The engagement underlines the
importance of Glycotope's technology platform. Octapharma is ideally
positioned to best leverage Glycotope's promising human blood coagulation
business," commented Dr. Thomas Strüngmann, main investor in Glycotope.
"This is the first strategic deal that covers a whole indication range of
Glycotope's portfolio and a huge endorsement of the GEXTM technology